One of the many learnings of the corona virus pandemic has been that consumer diagnostic testing for viruses and other ailments can be dramatically improved – especially if you can provide those diagnostics in an easy-to-use, at-home platform. NosTerra Ventures invested in Alveo, a leader in the transformation of the consumer health tech market with the development of a low-cost, easy-to-use, at-home diagnostic platform, as part of its effort to solve for the grand challenge of providing medicine and medical technology to continuously improve global health over the next 100 years.

Alveo’s be.well** testing platform has the potential to change the way infectious diseases are detected and managed. The system is designed to give individuals access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo’s agile and dynamic diagnostic platform could be adapted to detect a wide range of diseases that threaten public health.

Alveo and NosTerra Ventures believe that affordable access to real-time, at-home results will transform the way individuals, healthcare providers and public health professionals identify and manage disease outbreaks. With be.well™, consumers will Know Sooner, Act Faster™ and make better-informed decisions regarding personalized intervention options that benefit individuals and the entire population.

Ron Chiarello fits the mold of the entrepreneur that NosTerra Ventures invests in to transform an industry and to impugn the incumbents. Dr. Chiarello is the Founder, Chief Executive Officer, and Chairman of the Board of Alveo Technologies. He has led a distinguished career building on more than 25 years of expertise in designing, developing and manufacturing cutting-edge micro-fluidic, micro-electronics and semiconductor technologies. An entrepreneur at heart, Dr. Chiarello has successfully founded, led, and sold multiple startups specializing in applying these technologies to a range of sensing and diagnostic challenges.